Results of a registrational phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis) -

2025
Zhou K, Wang T, Niu T, Zheng M, Jin J, Liang Y, Huang R, Xu S, Qu J, Cui G, Li F, Luo Y, Feng R, Yu W, Li C, Yan Z, Zhou X, Wu S, Liu L, Geng Y, Wang J, Gao S, Fu J, Zhang X, Ji C, Xiang Q, Zhu X, Xu Y, Lin L, Zhu X, Zhong Y, Peng H, Zhao Y, Zeng H, Wang Z, Fu R, Qian W, Liang Y, Huang X, Li Y, Yu M, Chen Z, Wang L, Men L, Liang Z, Zeng S, Lu B, Zhai Y, Li J. Results of a registrational phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton’s tyrosine kinase inhibitors (BTKis). Blood. vol. 146(suppl 1):, pp. 88 (2025 ASH Oral Presentation)-88 (2025 ASH Oral Presentation),
View

Print